1. Home
  2. ABCL vs QURE Comparison

ABCL vs QURE Comparison

Compare ABCL & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.97

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$48.11

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABCL
QURE
Founded
2012
1998
Country
Canada
Netherlands
Employees
N/A
248
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.1B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
ABCL
QURE
Price
$5.97
$48.11
Analyst Decision
Strong Buy
Buy
Analyst Count
5
14
Target Price
$8.40
$45.00
AVG Volume (30 Days)
6.2M
2.5M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
10.91
29.67
EPS
N/A
N/A
Revenue
$75,128,000.00
$13,107,000.00
Revenue This Year
N/A
$126.12
Revenue Next Year
$21.85
$200.43
P/E Ratio
N/A
N/A
Revenue Growth
160.56
N/A
52 Week Low
$2.75
$8.73
52 Week High
$6.79
$71.50

Technical Indicators

Market Signals
Indicator
ABCL
QURE
Relative Strength Index (RSI) 60.46 75.61
Support Level $5.23 $21.63
Resistance Level $6.65 $60.70
Average True Range (ATR) 0.52 2.80
MACD -0.01 2.16
Stochastic Oscillator 56.38 92.06

Price Performance

Historical Comparison
ABCL
QURE

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: